The Hematologic Malignancies Program has two overarching scientific goals. These are to: 1. Employ state of the art technology to develop mechanisms based understanding of the cellular, biochemical, and molecular biology of normal and malignant hemato-lymphopoiesis. 2. Translate basic scientific discoveries into rational therapies that are more tumoricidal but at the same time, less toxic to normal tissues. To accomplish these goals, the investigators organize within thematic areas in both basic and clinical science. All areas focus on translation as a goal of the wori
Showing the most recent 10 out of 1047 publications